A new era of pharmaceutical pricing in the US is reportedly emerging, with some patients seeing lower drug prices. The timing of this development is unclear, with some sources suggesting it is already underway and others indicating it will arrive in 2026. The impact of these changes on the pharmaceutical industry and patients is still being assessed, with various stakeholders weighing in on the potential effects on market access, costs, and innovation.